Larimar Therapeutics (ZA71) AI Stock Analysis

Larimar Therapeutics

(Frankfurt:ZA71)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Regulatory progressFDA alignment on a novel surrogate endpoint and acceptance of a rolling BLA materially clarify the regulatory pathway for nomlabofusp. Submission progress can support development momentum and improve the company’s ability to pursue accelerated approval for its lead program.

Negative Factors

No commercial revenueZero revenue means Larimar has not yet established a commercial product base to fund operations or validate recurring demand. Until nomlabofusp is approved and launched, the business remains dependent on development success and external capital rather than operating revenue.

Larimar Therapeutics (ZA71) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 256.59M
Dividend Yield: ―
Average Volume (3M): 1,707
Price to Earnings (P/E): -1.2
Beta (1Y): 0.81
Revenue Growth: ―
EPS Growth: -18.05%
Country: Germany
Employees: 71
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Larimar Therapeutics Business Overview & Revenue Model

Company Description

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platf...

Larimar Therapeutics Risk Analysis

Larimar Therapeutics disclosed 85 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026; however, there can be no assurance that we will submit the remaining modules on our expected timeline, that the FDA will accept the BLA for filing or the FDA will approve our BLA submission for accelerated approval.Q2, 2026

Larimar Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:ZA71 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CADL	54Neutral	$637.40M	-5.91	-89.38%	―	―	-108.75%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	48Neutral	$1.33B	9.65	-109.40%	―	―	―
FHTX	42Neutral	$123.52M	-2.10	72.64%	―	51.98%	17.68%
VNDA	42Neutral	$229.18M	-0.82	-106.94%	―	8.11%	-222.50%
NMRA	38Underperform	$69.00M	-0.30	-242.28%	―	―	21.31%

* Healthcare Sector Average

Performance Comparison

DE:ZA71 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:ZA71	Larimar Therapeutics, Inc.	2.26	-1.00	-30.67%
OMER	Omeros Corporation	18.44	11.71	174.00%
VNDA	Vanda Pharmaceuticals	3.79	-0.56	-12.87%
FHTX	Foghorn Therapeutics, Inc.	2.08	-1.45	-41.08%
CADL	Candel Therapeutics, Inc.	8.33	3.20	62.38%
NMRA	Neumora Therapeutics, Inc.	0.37	-2.42	-86.85%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Larimar Therapeutics AI Stock Analysis